Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 320,026
▼ 46% vs 2024
Profit
Caution€ -2.5 million
▼ 16% vs 2024
Debts
Low€ 3.2 million
▲ 238% vs 2024
Perseus Biomics from Leuven, company number BE0650946412, closed financial year 2025 with a result of € -2.5 million after tax. For that financial year Perseus Biomics recorded a gross margin of € 320,026 and equity of € 2.1 million. Compared with financial year 2024, the result moved from € -2.1 million to € -2.5 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
What happened at Perseus Biomics?
What happened at Perseus Biomics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 2.5 million. Source: NBB ↗
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 483,075 loss in 2021 to € 2.5 million loss in 2025.
On average € 22,400 of value added per employee in 2025.
A new publication or filing at Perseus Biomics? We notify you, reason included.
Follow Perseus BiomicsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Perseus Biomics are Walid Hanna, Ahmed Diar, Volker Leen, Adam Roslewski, Thomas Prischenk and Johan Hofkens. It owns 100% of Perseus Agiome Limited Liability and 50% of Chrometra BV itself.
Directors
According to the 2025 annual accounts
Walid Hanna
Director
Ahmed Diar
Director
Adam Roslewski
Director
Thomas Prischenk
Director
Johan Hofkens
Director
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
ReWind Therapeutics
€ -528,262 gross margin · 2025
AUGUSTINE THERAPEUTICS
€ -1.7 million gross margin · 2025
Montis Biosciences
€ -2.1 million gross margin · 2025
+6 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
SQUARESPACE - Squarespace, Inc., US
DNS
DigitalOcean DNS
Domain
Domain
perseusbiomics.com
Registered
2015-12-09
Registrar
Gandi SAS
Expires
2026-12-09
Website info
Features
Security
Network
Details
- Company number
- 0650.946.412
- VAT number
- BE 0650.946.412
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- Perseus Biomics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 31 March 2016
- Peppol
- Active · Active since 9 Jan 2026
- Contact
- perseusbiomics.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van overige farmaceutische producten
Vervaardiging van geneesmiddelen